Cargando…

Emerging Biomarker-Guided Therapies in Prostate Cancer

Prostate cancer remains one of the leading causes of cancer death in men worldwide. In the past decade, several new treatments for advanced prostate cancer have been approved. With a wide variety of available drugs, including cytotoxic agents, androgen receptor axis-targeted therapies, and alpha-emi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deluce, Jasna E., Cardenas, Luisa, Lalani, Aly-Khan, Maleki Vareki, Saman, Fernandes, Ricardo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9319825/ https://www.ncbi.nlm.nih.gov/pubmed/35877260 http://dx.doi.org/10.3390/curroncol29070400

Ejemplares similares

Next Wave of Targets in the Treatment of Advanced Renal Cell Carcinoma
por: Cardenas, Luisa M., et al.
Publicado: (2022)

The role of gut microbiome in immune modulation in metastatic renal cell carcinoma
por: Deluce, Jasna, et al.
Publicado: (2022)

The Effect of the Gut Microbiota on Systemic and Anti-Tumor Immunity and Response to Systemic Therapy against Cancer
por: Aghamajidi, Azin, et al.
Publicado: (2022)

High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors
por: Maleki Vareki, Saman
Publicado: (2018)

Addressing the Elephant in the Immunotherapy Room: Effector T-Cell Priming versus Depletion of Regulatory T-Cells by Anti-CTLA-4 Therapy
por: Hong, Megan M Y, et al.
Publicado: (2022)

The emerging landscape of neo/adjuvant immunotherapy in renal cell carcinoma
por: Dibajnia, Pooya, et al.
Publicado: (2023)

Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Cancer and Immunotherapy
por: Krishnamoorthy, Mithunah, et al.
Publicado: (2021)

Immunomodulation in Pancreatic Cancer
por: Krishnamoorthy, Mithunah, et al.
Publicado: (2020)

Neoadjuvant Immunotherapy for High-Risk, Resectable Malignancies: Scientific Rationale and Clinical Challenges
por: Krishnamoorthy, Mithunah, et al.
Publicado: (2021)

Novel anti-cancer drug COTI-2 synergizes with therapeutic agents and does not induce resistance or exhibit cross-resistance in human cancer cell lines
por: Maleki Vareki, Saman, et al.
Publicado: (2018)

The Role of Microbiota-Derived Vitamins in Immune Homeostasis and Enhancing Cancer Immunotherapy
por: Gholami, Hasti, et al.
Publicado: (2023)

COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo
por: Salim, Kowthar Y., et al.
Publicado: (2016)

Enhanced donor screening for faecal microbial transplantation during COVID-19
por: Parvathy, Seema Nair, et al.
Publicado: (2021)

HPV-Positive and -Negative Cervical Cancers Are Immunologically Distinct
por: Evans, Andris M., et al.
Publicado: (2022)

The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer
por: Naqash, Abdul Rafeh, et al.
Publicado: (2021)

Moving on from Metchnikoff: thinking about microbiome therapeutics in cancer
por: Vareki, Saman Maleki, et al.
Publicado: (2018)

Correction: COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo
por: Salim, Kowthar Y., et al.
Publicado: (2017)

Glial activation positron emission tomography imaging in radiation treatment of breast cancer brain metastases
por: Badiuk, Sawyer Rhae, et al.
Publicado: (2022)

Inhibition of BRCA2 and Thymidylate Synthase Creates Multidrug Sensitive Tumor Cells via the Induction of Combined “Complementary Lethality”
por: Rytelewski, Mateusz, et al.
Publicado: (2013)

Improved MAIT cell functions following fecal microbiota transplantation for metastatic renal cell carcinoma
por: Ninkov, Marina, et al.
Publicado: (2022)

Treatment-naïve HPV+ head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV- counterparts that has implications for immunotherapy
por: Gameiro, Steven F., et al.
Publicado: (2018)

The effects of bare metal versus drug-eluting stent implantation on circulating endothelial cells following percutaneous coronary intervention(*)
por: Jazi, Seyed Mohammad Hashemi, et al.
Publicado: (2011)

Real-World Evidence of Systemic Therapy Sequencing on Overall Survival for Patients with Metastatic BRAF-Mutated Cutaneous Melanoma
por: Kartolo, Adi, et al.
Publicado: (2022)

BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma
por: Labadie, Brian W., et al.
Publicado: (2019)

Emerging biomarkers of prostate cancer (Review)
por: MARTIN, SARAH K., et al.
Publicado: (2012)

Emerging biomarkers in the diagnosis of prostate cancer
por: Filella, Xavier, et al.
Publicado: (2018)

EVALUATING HUMAN MICROBIOME SIGNATURES ASSOCIATED WITH DEVELOPMENT, OUTCOME, AND TREATMENT RESPONSE IN GLIOMA AND BRAIN METASTASIS: A SCOPING REVIEW
por: Leigh, J, et al.
Publicado: (2023)

Indoleamine 2,3-dioxygenase mediates immune-independent human tumor cell resistance to olaparib, gamma radiation, and cisplatin
por: Vareki, Saman Maleki, et al.
Publicado: (2014)

siRNA knockdown of mitochondrial thymidine kinase 2 (TK2) sensitizes human tumor cells to gemcitabine
por: Di Cresce, Christine, et al.
Publicado: (2015)

IDO Downregulation Induces Sensitivity to Pemetrexed, Gemcitabine, FK866, and Methoxyamine in Human Cancer Cells
por: Maleki Vareki, Saman, et al.
Publicado: (2015)

Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies
por: Michielin, Olivier, et al.
Publicado: (2022)

Emerging proteomics biomarkers and prostate cancer burden in Africa
por: Adeola, Henry A., et al.
Publicado: (2017)

Prostate Cancer Imaging and Biomarkers Guiding Safe Selection of Active Surveillance
por: Glaser, Zachary A., et al.
Publicado: (2017)

Tissue Biomarkers for Prostate Cancer Radiation Therapy
por: Tran, PT, et al.
Publicado: (2012)

Focal Therapy in the Management of Prostate Cancer: An Emerging Approach for Localized Prostate Cancer
por: Nomura, Takeo, et al.
Publicado: (2012)

TdIF1-LSD1 Axis Regulates Epithelial—Mesenchymal Transition and Metastasis via Histone Demethylation of E-Cadherin Promoter in Lung Cancer
por: Liu, Qi, et al.
Publicado: (2021)

Volatilomics: An Emerging and Promising Avenue for the Detection of Potential Prostate Cancer Biomarkers
por: Berenguer, Cristina V., et al.
Publicado: (2022)

MRI-guided biopsies and minimally invasive therapy for prostate cancer
por: Ghai, Sangeet, et al.
Publicado: (2015)

MR Imaging in Real Time Guiding of Therapies in Prostate Cancer
por: Wimper, Yvonne, et al.
Publicado: (2022)

Emerging Targeted Therapies for Castration-Resistant Prostate Cancer
por: Adamo, Vincenzo, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_6tsaic1gh4s5lsjcnqvbe02rmb